PUBLIC LAW 109–417—DEC. 19, 2006
120 STAT. 2867
‘‘(c) BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY.— ‘‘(1) ESTABLISHMENT.—There is established within the Department of Health and Human Services the Biomedical Advanced Research and Development Authority. ‘‘(2) IN GENERAL.—Based upon the strategic plan described in subsection (b), the Secretary shall coordinate the acceleration of countermeasure and product advanced research and development by— ‘‘(A) facilitating collaboration between the Department of Health and Human Services and other Federal agencies, relevant industries, academia, and other persons, with respect to such advanced research and development; ‘‘(B) promoting countermeasure and product advanced research and development; ‘‘(C) facilitating contacts between interested persons and the offices or employees authorized by the Secretary to advise such persons regarding requirements under the Federal Food, Drug, and Cosmetic Act and under section 351 of this Act; and ‘‘(D) promoting innovation to reduce the time and cost of countermeasure and product advanced research and development. ‘‘(3) DIRECTOR.—The BARDA shall be headed by a Director (referred to in this section as the ‘Director’) who shall be appointed by the Secretary and to whom the Secretary shall delegate such functions and authorities as necessary to implement this section. ‘‘(4) DUTIES.— ‘‘(A) COLLABORATION.—To carry out the purpose described in paragraph (2)(A), the Secretary shall— ‘‘(i) facilitate and increase the expeditious and direct communication between the Department of Health and Human Services and relevant persons with respect to countermeasure and product advanced research and development, including by— ‘‘(I) facilitating such communication regarding the processes for procuring such advanced research and development with respect to qualified countermeasures and qualified pandemic or epidemic products of interest; and ‘‘(II) soliciting information about and data from research on potential qualified countermeasures and qualified pandemic or epidemic products and related technologies; ‘‘(ii) at least annually— ‘‘(I) convene meetings with representatives from relevant industries, academia, other Federal agencies, international agencies as appropriate, and other interested persons; ‘‘(II) sponsor opportunities to demonstrate the operation and effectiveness of relevant biodefense countermeasure technologies; and ‘‘(III) convene such working groups on countermeasure and product advanced research and development as the Secretary may determine are necessary to carry out this section; and
VerDate 14-DEC-2004
09:16 Jul 13, 2007
Jkt 059194
PO 00003
Frm 00346
Fmt 6580
Sfmt 6581
E:\PUBLAW\PUBL003.109
APPS06
PsN: PUBL003
�
